Purpose: Any association between the CYP1B1 C4326G polymorphism and endometrial cancer risk remains inconclusive. In order to provide a more precise estimate, we performed the present meta-analysis. Methods: We used fixed effect or random effect models to estimate pooled odds ratios (ORs) with 95% confidence intervals (CIs) for endometrial cancer risk, with the Chi-square-based Q-test used to test for heterogeneity. Begg’s and Egger’s tests were adopted to check publication bias. Results: Six published case-control studies of association between the CYP1B1 C4326G polymorphism and endometrial cancer risk covering 6,577 subjects were included in the meta-analysis, but the results indicated no significant correlation with allele contrast and genotype comparisons (G vs C: OR 1.01, 95% CI 0.93-1.09; GG vs CC: OR 1.04, 95% CI 0.88-1.23; CG + GG vs CC: OR 1.08, 95% CI 0.97-1.21; GG vs CC + CG: OR 1.01, 95% CI 0.87-1.17). Heterogeneity hypothesis test did not reveal any heterogeneity and Begg’s and Egger’s tests did not detect obvious publication bias. Conclusions: There is no association between the CYP1B1 C4326G polymorphism and endometrial cancer risk.
(2011). No Association Between the CYP1B1 C4326G Polymorphism and Endometrial Cancer Risk: a Meta-analysis. Asian Pacific Journal of Cancer Prevention, 12(9), 2343-2348.
MLA
. "No Association Between the CYP1B1 C4326G Polymorphism and Endometrial Cancer Risk: a Meta-analysis". Asian Pacific Journal of Cancer Prevention, 12, 9, 2011, 2343-2348.
HARVARD
(2011). 'No Association Between the CYP1B1 C4326G Polymorphism and Endometrial Cancer Risk: a Meta-analysis', Asian Pacific Journal of Cancer Prevention, 12(9), pp. 2343-2348.
VANCOUVER
No Association Between the CYP1B1 C4326G Polymorphism and Endometrial Cancer Risk: a Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2011; 12(9): 2343-2348.